Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMS III stroke reperfusion trial
NL-OMON36365Phase 3Active, not recruiting
- Sponsor
- National Institutes of Health
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator in ischemic stroke (2 arms), sponsored by National Institutes of Health. Primary endpoint: Favorable functional outcome at 3 months. Started Sep 2011; status: active, not recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NL-OMON36365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36365.